The General Counsel, Lori M. Henderson for the stocks of MRNA has sold over 6,600 shares of the business in an 8th April transaction. The average price of the stocks has been set at $132.85, with a transaction coming to a total value of $876,810.00. The general counsel currently has control of almost 7,501 shares in the company. The SEC has a legal filing of the document which is available on the official site.
The Quarterly Estimates Of MRNA
The stocks of MRNA traded on Friday at $7.01, with a moving average price of the company over 50 days set at $142.05, with the moving average price of the company over 200 days set at $120.49. The debt-to-equity ratio of the company was 0.04, with a 2.43 current ratio, with a 2.43 quick ratio. The year low of the company is $31.32, with a year high of $189.26. The market cap of the firm is $56.43 billion, with a -88.38 PE ratio, with a 0.53 PEG ratio.
MRNA had uploaded its previous earnings report on the 25th of February. The EPS reported by the company was $0.69, with the consensus estimate of about $0.25 EPS. The company had a 28.11% negative return on its equity, with a -242.73% net margin. The revenue of the company during this period was $570.80 million, with a consensus of $279.41 million.
There have been quite a few research equities that have reported on the stocks of MRNA. Morgan Stanley has already decreased the price target of the company from $215 to $201, with a rating of equal weight in a 4th March research report.
Goldman Sachs has also put up a rating of buy with a price target of around $139 in an 18th February research report. Chardan Capital has increased the price target of the company from a sum of $107 to a sum of $182 with a price rating of “buy” in an 8th March research report. In the end, SVB Leerink also increased the price target of MRNA from $69 to $80 with a rating of “outperform” in a 1st February research report.